Smith & Nephew（SNNU.F）株式概要スミス・アンド・ネフュー plc は、その子会社とともに、英国、米国、および海外で医療機器およびサービスの開発、製造、マーケティング、販売を行っています。 詳細SNNU.F ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長1/6過去の実績4/6財務の健全性5/6配当金5/6報酬当社が推定した公正価値より21.7%で取引されている 収益は年間12.7%増加すると予測されています 過去1年間で収益は51.7%増加しました 2.56%の安定した配当金を支払う アナリストらは、株価が24.3%上昇するだろうとほぼ一致している。 リスク分析株式の流動性は非常に低い 多額の負債を抱えている すべてのリスクチェックを見るSNNU.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$14.912.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture08b2016201920222025202620282031Revenue US$8.1bEarnings US$819.3mAdvancedSet Fair ValueView all narrativesSmith & Nephew plc 競合他社Zimmer Biomet HoldingsSymbol: NYSE:ZBHMarket cap: US$16.3bPenumbraSymbol: NYSE:PENMarket cap: US$12.9bSTERISSymbol: NYSE:STEMarket cap: US$21.2bMasimoSymbol: NasdaqGS:MASIMarket cap: US$9.4b価格と性能株価の高値、安値、推移の概要Smith & Nephew過去の株価現在の株価UK£14.9152週高値UK£18.5052週安値UK£14.15ベータ0.671ヶ月の変化-7.85%3ヶ月変化-17.17%1年変化4.93%3年間の変化0.47%5年間の変化-31.29%IPOからの変化150.59%最新ニュースお知らせ • May 07+ 1 more updateSmith & Nephew plc (LSE:SN.) announces an Equity Buyback for $500 million worth of its shares.Smith & Nephew plc (LSE:SN.) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its shares. The program will be financed from free cash flow and existing cash balances. The program will be valid for 12 months.お知らせ • May 06Smith & Nephew plc to Report Q2, 2026 Results on Aug 04, 2026Smith & Nephew plc announced that they will report Q2, 2026 results on Aug 04, 2026お知らせ • Apr 22SMITH & NEPHEW PLC Announces New Data for Cartiheal Agili-C Cartilage Repair ImplantSMITH & NEPHEW PLC announced further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care for all time points out to 60 months. Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year period. Patients treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport and recreation at 2, 4 and 5-years. Equal clinical outcomes were found in OA and non-OA patients receiving the CARTIHEAL Implant. Smith+Nephew's FDA-approved CARTIHEAL Implant is revolutionizing the cartilage repair landscape with the implant's broad indication allowing physicians to treat patients who previously may not have had access. The implant recently received a Category I Current Procedural Terminology (CPT) code for procedures that will go into effect on January 1, 2027.お知らせ • Apr 10Smith+Nephew Announces Significant Outcome Improvements for Regeneten Bioinductive Implant in Partial-Thickness Rotator Cuff TearsSmith+Nephew announced compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the REGENETEN Bioinductive Implant in isolation. Compared with a traditional suture anchor repair, early recovery time was halved for patients returning to daily activities such as: Driving: 2.3 vs 5.1 weeks, Office work: 1.7 vs 3.6 weeks (p=0.009), Moderate-intensity household chores: 3.8 vs 8.4 weeks. The study, recently published in the Orthopaedic Journal of Sports Medicine, also concluded that REGENETEN Implant patients enjoyed a better quality of life at 6 weeks and 3 months, and high rates of tendon healing at 1 year, comparable to suture anchor-based repairs. This is the third RCT demonstrating that the REGENETEN Bioinductive Implant improves outcomes versus traditional rotator cuff repair techniques. With more than 250,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for thousands of patients with rotator cuff injuries every year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs. This evidence follows the recent revision to the American Academy of Orthopaedic Surgeons Clinical Practice Guideline on the ‘Management of Rotator Cuff Injuries’ which highlights the value of bioinductive implants in rotator cuff repair based on an independent analysis of studies. The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair.お知らせ • Mar 17Smith & Nephew plc, Annual General Meeting, May 06, 2026Smith & Nephew plc, Annual General Meeting, May 06, 2026. Location: the smith nephew academy london, building 5, croxley park, hatters lane, wd18 8ye., watford 8ye., watford United Kingdomお知らせ • Mar 11Smith+Nephew Launches Allevyn Complete Care Foam DressingSmith+Nephew recently announced the launch of ALLEVYN COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence. ALLEVYN COMPLETE CARE Dressing has a unique five-layer construction with distinct mode of action technologies targeted towards both wound management and pressure injury prevention. Minimising leakage and disruption by fewer dressing changes, and protecting vulnerable skin are essential to achieving this goal. Global estimates suggest that up to one in 50 adults are affected by chronic wounds in their lifetime, facing delayed healing and complications that impact daily life. Studies report up to one in 10 hospitalised patients are affected by pressure injuries, with hospital-acquired pressure injuries associated with an average of 9.5 additional days of hospital stay. Pressure injuries and chronic wounds continue to place a significant burden on the broader healthcare system. ALLEVYN COMPLETE CARE Dressing’s proprietary technologies have advanced capabilities that are designed to help clinicians care with confidence. The dressing was developed to address the needs of both wound management and pressure injury prevention, informed by collaboration with healthcare professionals and patients worldwide. It is proven to lock in significantly more exudate than other foam dressings while keeping over 99% of bacteria away from the wound bed. This minimises leakage, enables longer wear times for undisturbed healing, and has potential to release over 10% of valuable nursing time. Unbonded sliding layers within the dressing absorb up to 93% of mechanical energy, helping to reduce the risk of pressure injury by over 65%. ALLEVYN COMPLETE CARE Dressing’s unbonded multilayer structure delivers a distinct mode of action that helps dissipate shear forces before they reach the skin and underlying soft tissues. This pioneering technology protects soft tissue and minimises the risk of developing a pressure injury. ALLEVYN COMPLETE CARE Dressing is available in five different shapes and a variety of sizes to meet a diverse range of wound care needs. Initially available in the US, the dressing will be launching in many European and other international markets in 2026 as the company continue to support patients’ unique needs, and shape what’s possible in wound care.最新情報をもっと見るRecent updatesお知らせ • May 07+ 1 more updateSmith & Nephew plc (LSE:SN.) announces an Equity Buyback for $500 million worth of its shares.Smith & Nephew plc (LSE:SN.) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its shares. The program will be financed from free cash flow and existing cash balances. The program will be valid for 12 months.お知らせ • May 06Smith & Nephew plc to Report Q2, 2026 Results on Aug 04, 2026Smith & Nephew plc announced that they will report Q2, 2026 results on Aug 04, 2026お知らせ • Apr 22SMITH & NEPHEW PLC Announces New Data for Cartiheal Agili-C Cartilage Repair ImplantSMITH & NEPHEW PLC announced further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care for all time points out to 60 months. Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year period. Patients treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport and recreation at 2, 4 and 5-years. Equal clinical outcomes were found in OA and non-OA patients receiving the CARTIHEAL Implant. Smith+Nephew's FDA-approved CARTIHEAL Implant is revolutionizing the cartilage repair landscape with the implant's broad indication allowing physicians to treat patients who previously may not have had access. The implant recently received a Category I Current Procedural Terminology (CPT) code for procedures that will go into effect on January 1, 2027.お知らせ • Apr 10Smith+Nephew Announces Significant Outcome Improvements for Regeneten Bioinductive Implant in Partial-Thickness Rotator Cuff TearsSmith+Nephew announced compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the REGENETEN Bioinductive Implant in isolation. Compared with a traditional suture anchor repair, early recovery time was halved for patients returning to daily activities such as: Driving: 2.3 vs 5.1 weeks, Office work: 1.7 vs 3.6 weeks (p=0.009), Moderate-intensity household chores: 3.8 vs 8.4 weeks. The study, recently published in the Orthopaedic Journal of Sports Medicine, also concluded that REGENETEN Implant patients enjoyed a better quality of life at 6 weeks and 3 months, and high rates of tendon healing at 1 year, comparable to suture anchor-based repairs. This is the third RCT demonstrating that the REGENETEN Bioinductive Implant improves outcomes versus traditional rotator cuff repair techniques. With more than 250,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for thousands of patients with rotator cuff injuries every year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs. This evidence follows the recent revision to the American Academy of Orthopaedic Surgeons Clinical Practice Guideline on the ‘Management of Rotator Cuff Injuries’ which highlights the value of bioinductive implants in rotator cuff repair based on an independent analysis of studies. The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair.お知らせ • Mar 17Smith & Nephew plc, Annual General Meeting, May 06, 2026Smith & Nephew plc, Annual General Meeting, May 06, 2026. Location: the smith nephew academy london, building 5, croxley park, hatters lane, wd18 8ye., watford 8ye., watford United Kingdomお知らせ • Mar 11Smith+Nephew Launches Allevyn Complete Care Foam DressingSmith+Nephew recently announced the launch of ALLEVYN COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence. ALLEVYN COMPLETE CARE Dressing has a unique five-layer construction with distinct mode of action technologies targeted towards both wound management and pressure injury prevention. Minimising leakage and disruption by fewer dressing changes, and protecting vulnerable skin are essential to achieving this goal. Global estimates suggest that up to one in 50 adults are affected by chronic wounds in their lifetime, facing delayed healing and complications that impact daily life. Studies report up to one in 10 hospitalised patients are affected by pressure injuries, with hospital-acquired pressure injuries associated with an average of 9.5 additional days of hospital stay. Pressure injuries and chronic wounds continue to place a significant burden on the broader healthcare system. ALLEVYN COMPLETE CARE Dressing’s proprietary technologies have advanced capabilities that are designed to help clinicians care with confidence. The dressing was developed to address the needs of both wound management and pressure injury prevention, informed by collaboration with healthcare professionals and patients worldwide. It is proven to lock in significantly more exudate than other foam dressings while keeping over 99% of bacteria away from the wound bed. This minimises leakage, enables longer wear times for undisturbed healing, and has potential to release over 10% of valuable nursing time. Unbonded sliding layers within the dressing absorb up to 93% of mechanical energy, helping to reduce the risk of pressure injury by over 65%. ALLEVYN COMPLETE CARE Dressing’s unbonded multilayer structure delivers a distinct mode of action that helps dissipate shear forces before they reach the skin and underlying soft tissues. This pioneering technology protects soft tissue and minimises the risk of developing a pressure injury. ALLEVYN COMPLETE CARE Dressing is available in five different shapes and a variety of sizes to meet a diverse range of wound care needs. Initially available in the US, the dressing will be launching in many European and other international markets in 2026 as the company continue to support patients’ unique needs, and shape what’s possible in wound care.お知らせ • Mar 04Smith+Nephew to Showcase Advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma Technologies During AAOS 2026Smith+Nephew announced it will feature handheld robotics and digital solutions for hip, knee and shoulder in addition to innovative trauma and extremities products during the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. Some of the company’s latest Orthopaedics advancements and highlighted technologies include: Handheld Robotics: Optimizing and Personalizing Surgery. As the leader in handheld robotics, the CORI? Surgical System delivers a digital surgery ecosystem–spanning solutions from advanced pre-operative planning and a connected post-operative data management solution. The entire robotics ecosystem is designed to amplify the surgeon experience and expertise and has shown improvements in accuracy and patient outcomes in joint arthroplasty. Smith+Nephew’s CORIOGRAPH? Pre-Op Planning and Modeling Services enables optimization of handheld robotic knee and shoulder arthroplasty and computer guided hip – further personalizing surgery for both surgeons and their patients. CORIOGRAPH Pre-Op Planning and Modeling Services + CORI Surgical System supports several image modalities - allowing for a new dimension of pre-operative planning for each individual patient - and supporting the intra-operative surgical workflow. In the booth at AAOS, Smith+Nephew will have a motion capture lounge demonstrating how 3-D modeling of patient motion is important in planning implant position and advanced simulated activities of daily living. CORI XT is required for shoulder application. CORI SHOULDER Robotic Shoulder Arthroplasty with the AETOS? Shoulder System: Differentiated Technology for Personalized Care. In the fast-growing shoulder market, the CORI SHOULDER Platform is well positioned to meet the unmet needs of surgeons who demand both accuracy and procedural efficiency. The system is specifically optimized for use with the AETOS Shoulder System. It features the CORI Handheld Robotic Platform technology and supports robotic preparation of both humeral and glenoid execution for shoulder arthroplasty. Smith+Nephew advances robotic shoulder arthroplasty with a complete, handheld solution that supports seamless integration and workflow efficiencies for shoulder arthroplasty. The procedure represents a significant leap forward in the shoulder arthroplasty space, perfectly suited for the constraints of the anatomy and supported by a portable footprint for flexibility in the hospital or ASC. Last week, the first ever CORI SHOULDER Robotic Shoulder Arthroplasty cases were completed, performed by a surgical team at Duke Health led by Dr. Christopher Klifto. To learn more, please visit the CORI SHOULDER website or see a live demo of CORI SHOULDER Robotic Shoulder Arthroplasty at AAOS in Booth #839. Advanced Implant Science. Get the latest clinical data and insights on our flagship implant options for hip, knee and shoulder arthroplasty including recent additions to our portfolio such as LEGION? Total Knee Medial Stabilized System, CATALYSTEM? Primary Hip System and the AETOS Shoulder System stemless option. Trauma Advancements. From reduction to fixation, the EVOS? LARGE & PERIPROSTHETIC Plating System has evolved to give surgeons stability and flexibility with one screw design for threaded locking, and variable-angle locking and compatibility with the EVOS Cabling System. We will also be expanding the EVOS portfolio this year with the launch of the EVOS PELVIC System. TRIGEN? MAX Tibia Nailing System is the only system to give trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options. Come visit Smith+Nephew at Booth #839 and hear about the expansion of TRIGEN MAX Tibia this year. Smith+Nephew has also recently signed distribution agreements with SI-BONE, focused on their innovative iFuse TORQ portfolio for pelvic fractures and RMR Ortho for the A’TOMIC™ Nitinol Fixation System, a compression fixation option for trauma cases. At the ASC suite, Smith+Nephew will provide customers with a preview of our expanded enterprise ASC offering—an end-to-end solution designed to support both de novo ASC development and the modernization of existing facilities. This comprehensive model enables customers to finance, design, build, equip, and optimize their centers through one coordinated, streamlined pathway. Through new strategic partnerships with Brasfield & Gorrie, Ghafari Associates, Unity Health Centers, and STERIS, we are bringing best-in-class expertise and technologies together into a single, aligned delivery model—helping customers accelerate timelines, reduce complexity, and drive operational performance from day one.お知らせ • Mar 03+ 1 more updateSmith & Nephew plc Recommends Final Dividend for 2025, Payable on May 27, 2026Smith & Nephew plc announced the Board is recommending a Final Dividend of 24.1 US cents per share for 2025(48.2 US cents per ADS) (2024: 23.1 US cents per share). Together with the Interim Dividend of 15.0 US cents per share (30.0 US cents per ADS) (2024: 14.4 US cents), this will give a total distribution of 39.1 US cents per share (78.2 US cents per ADS), a 4.3% increase from 2024. The 38% payout ratio is in line with the 35-40% indicated in our capital allocation framework. The dividend will be paid, subject to shareholder approval, on 27 May 2026 to shareholders whose names appear on the Register of Members on 27 March 2026. The sterling equivalent per ordinary share will be set following the record date. The ex-dividend date is 26 March 2026 and the final day for currency and dividend reinvestment plan (‘DRIP’) elections is 5 May 2026.お知らせ • Jan 22Smith & Nephew plc (LSE:SN.) completed the acquisition of Integrity Orthopaedics, Inc.Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million on January 12, 2026. The transaction is expected to close by end of January 2026. Pran Jha, Joe Michaels, Danielle Haikal, Hannah Ellis, Kathy Jara, McKenna Chadwick, Parker Whitlow, Lauren Grau, Dina Kang, Patrick Donaldson, Lauren Gallagher, Amanda Casanueva, Nicholas Carballo, Cathryn Le Regulski, Kristina Daisak, Torrey Cope, Kelly Cho, Lauren Limbach, Elizabeth Hardcastle, Melody Mostow, Gabrielle Feliciani, Ash Nagdev, Sasha Hondagneu-Messner, Liz McCloy, Brandon Bryer, Suresh Advani and George Chen of Sidley Austin LLP acted as legal advisors for Smith & Nephew plc. Smith & Nephew plc (LSE:SN.) completed the acquisition of Integrity Orthopaedics, Inc. on January 21, 2026.お知らせ • Jan 13Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million.Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million on January 12, 2026. The transaction is expected to close by end of January 2026.お知らせ • Nov 07+ 1 more updateSmith & Nephew plc Maintains Earnings Guidance for the Full Year of 2025Smith & Nephew plc maintained earnings guidance for the full year of 2025. For the year, the company expects trading profit margin to expand to between 19.0% and 20.0%, a significant step-up year-on-year (2024: 18.1%), outlook includes an expected net impact of $15 million to $20 million from tariffs in 2025, based on announced measures, and mitigations, as previously stated.お知らせ • Nov 06Smith & Nephew plc to Report Fiscal Year 2025 Results on Mar 02, 2026Smith & Nephew plc announced that they will report fiscal year 2025 results on Mar 02, 2026お知らせ • Oct 28Smith+Nephew Announces Findings from A Newly Published, First-Of-Its-Kind comparative Study of Single-Use Negative Pressure Wound Therapy Devices inorthopedic and Cardiovascular SurgerySmith+Nephew announced findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery. Analyzing real-world data from over 22,000 patients in the Premier PINC AI™? Healthcare Database, the analysis reveals that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces the risk of wound dehiscence, hospital length of stay (LoS), and overall healthcare costs compared to the PrevenaTM -125 mmHg sNPWT device. An estimated 313 million surgical procedures are performed worldwide each year, with the number continuing to rise. In the United States, surgical site infections (SSIs) occur in approximately 2% to 4% of patients undergoing inpatient procedures. In relation to PrevenaTM sNPWT (-125mmHg), use of PICO sNPT (-80mmHg) resulted in the following key study findings: Cardiovascular Surgery (5,000+ patients) 57.8% relative reduction in wound dehiscence risk (P 9.1% relative reduction in LoS (6.33 days vs. 6.86 days) (P 10.34% relative reduction in admission-related costs and 13% lower expenditures within three months post-surgery (P Orthopedic Surgery (17,000+ patients) 63.9% relative reduction in wound deHiscence incidence (p 29.7% relative reduction in LoS(2.43 days vs. 3.10 days) (pp 21.95% relative reduction in mean index admission cost and a 21% reduction at 30- and 90-day post-surgery. These findings complement the growing evidence supporting prophylactic use of incisional negative pressure wound therapy (iNPWT) across surgery. A recent meta-analysis presented at the International Consensus Meeting 2025 concluded that "The use of iNPWT is recommended to minimize the risk of SSI in adult patients with primarily closed surgical incisions after lower extremity/acetabular fracture surgery and joint arthroplasty of the hip and knee." These findings are aligned with the global recommendations including NICE4, WHO5 and the ACS/SIS6 guidelines, all of which recommend the use of iNPWT for the purpose of reducing the risk of SSI for at risk patients.お知らせ • Sep 13Smith+Nephew Unveils Major Clinical Evidence and Patient Access Updates for its REGENETEN Bioindictive ImplantSmith+Nephew announced new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to help surgeons treat more patients who suffer from rotator cuff tears and other tendon and extra-articular ligament injuries throughout the body: AAOS Clinical Practice Guideline (CPG) on the Management of Rotator Cuff Injuries: For the first time, recent updates to the American Academy of Orthopaedic Surgeons (AAOS) CPG on the Management of Rotator Cuff Injuries highlight the value of bioinductive implants in rotator cuff repair, based on independent analysis of studies: AAOS CPGs provide evidence-based recommendations for current orthopaedic diagnostic, treatment, and postoperative procedures; Analyzing RCTs for bioinductive implants, AAOS have issued a StrongRecommendation that: ‘The use of bioinductive tendon implants to augment rotator cuff repair, or as an alternative to standard repair, can lead to lower re-tear rates and better patient reported outcomes.’ Randomized Controlled Trial (RCT) Results: Two-year results of the MALLAMANGUITO RCT from Dr. Miguel A. Ruiz Ibán and colleagues demonstrated a sustained 65% relative reduction in re-tear rates when using the REGENETEN Bioinductive Implant to augment repair of full-thickness rotator cuff tears: Two-year re-tear rates were 12.3% (7/57) with the REGENETEN Implant vs. 35.1% (20/57) with standard repair (p=0.004).These results build on previously reported 1-year results which have already made a significant impact in supporting patient access and adoption. Extra-articular Ligaments: For the first time, Smith+Nephew is able to market the REGENETEN Bioinductive Implant for extra-articular ligament injuries in the US. This new indication expansion offers opportunities to reach more patients with soft tissue injuries throughout the body. It will initially focus on hip capsule repair with abundant opportunities for future expansions in other extra-articular ligament repairs.With more than 150,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for the more than 1 million people having tendon or extra-articular ligament repair each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs and support natural healing processes. The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair.お知らせ • Sep 03Smith+Nephew Extends Advanced Wound Bioactives Portfolio with US Launch of Centrio Platelet-Rich-Plasma SystemSmith+Nephew announced the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment. CENTRIO PRP System can help manage chronic exuding wounds including but not limited to diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, and tunnelling wounds. Due to a National Coverage Determination (NCD) made effective April 2021, autologous PRP for the treatment of chronic non-healing wounds for diabetic patients has CMS coverage, when prepared by devices whose indications include the management of exuding cutaneous wounds, such as diabetic ulcers.1 The CENTRIO PRP System is designed for point-of-care use in both hospital and physician office settings and the gel can be tailored to fit wound shape, depth, and stage with a single draw of a patient's blood. CENTRIO PRP system has demonstrated efficacy in two randomized, controlled clinical trials2,3, making it a strong fit in Smith+Nephew's clinically proven portfolio. The CENTRIO PRP system will premiere at the Smith+Nephew booth during the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas, Nevada from September 3-6. Smith+Nephew entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc., a commercial stage medical device company pioneering biodynamic therapies, to market the CENTRIO PRP System in the United States.お知らせ • Aug 28Smith & Nephew plc Announces Dr Garheng Kong Will Join as an Independent Non-Executive Director and Member of the Audit Committee, Effective September 1, 2025Smith & Nephew plc announced that Dr Garheng Kong will join the Board as an independent Non-Executive Director and a member of the Audit Committee with effect from 1 September 2025. Garheng is currently managing partner and co-founder of HealthQuest Capital. He also serves as lead independent director of Laboratory Corporation of America (LabCorp) and a non-executive director of Xeris Biopharma Holdings Inc, Lunit Inc. and IKS Health. Garheng was previously managing general partner of Sofinnova Investments Inc. and served as a non-executive director of Venus Concept, Inc, Alimera Sciencesand Avedro Inc. and as chair of Histogenics Corporation.お知らせ • Jul 07Smith+Nephew Announces the Release of Its Q-Fix Knotless All-Suture Anchor for Soft Tissue-To-Bearing Indications Across Multiple Joint Spaces Including Shoulder, Hip, Hip, and Foot & AnkleSmith+Nephew announced the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including shoulder, Hip, and Foot & Ankle. Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices, the new Q-FIX KNOTless All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS all-Suture Anchor aims to set a new benchmark for fixation strength and offer surgeons a reason to reassess their joint repair approach, including: Market-leading strength in all-suture anchor fixation1-5 and ultra-low displacement1,6-10 Consistent deployment4,11,12, Best-in-class soft tissue security with suture lock mechanism. Streamlined suture shuttling5, Market-leading biomechanical performance,+ 1-4,6,7 with the lowest displacement during cyclic loading++1,3,6,7 The Q-FIX KNOTless all-Sutures Anchor offers a versatile range of suture options that include both single-loaded MinITAPE Suture Tape - which has a low profile and coreless design to offer a lower and more evenly distributed level of pressure13,14 or ULTRABRAID #2 Suture that is 20% stronger than its nearest competitor.お知らせ • Jun 24+ 1 more updateSmith+Nephew Announces the Launch of Its New Trigen Max Tibial Nailing System for Stable and Institutional Fulfillment of the Tibia, Including the ShaftSmith+Nephew announced the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw corridors, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options. The TRIGEN MAX TibiaNailing System aims to streamline operative procedures and provide efficiency through surgeon-centered design of components and instrumentation, including: Two-piecemodular drop system to help when using ancillary instruments and aid visualization. 12.5mm channel reamer for the tibia which is designed to preserve the integrity of the entry point and provide soft tissue protection. 5.0mm Lag Screws that compress the fracture in one screw insertion step, creating a streamlined workflow. The new TRIGEN MAX Tibial Nailing System is poised to be the next product setting the standard of care and performance for intramedullary nails. The TRIGEN MAXibia Nailing System is currently available in the United States only.お知らせ • Jun 13Smith & Nephew plc Appoints David King as an Independent Non-Executive Director and Member of the Compliance & Culture and the Remuneration Committees, Effective 1 July 2025Smith & Nephew plc announced that David King will join the Board as an independent Non-Executive Director with effect from 1 July 2025. David will serve as a member of the Compliance & Culture and the Remuneration Committees. David is currently CEO, executive director and chair of Fortis Life Sciences. He also serves, or has recently served, as a Chair or non-executive director on the boards of several US healthcare companies including ZimVie (2022 - 2025), VaxCare (2021 - 2025), Privia Health, Health Channels, LGC and AmSurg Corporation. David served as executive chair and CEO for Laboratory Corporation of America (LabCorp) from 2007 to 2020 and prior to that was a partner at Hogan & Hartson LLP (now Hogan Lovells).お知らせ • Jun 10Smith+Nephew Announces the Introduction of A New Medial Stabilized Insert for Its Legion Total Knee SystemSmith+Nephew announced the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023. With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone- conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient. The medial stabilized design aims to maintain stability with a larger anterior medial lip and medial pivot kinematics similar to the natural knee. The LEGION Medial Stabilized TKS stands out in this space - offering a powerful combination of medial stabilized kinematics, advanced porous fixation, integration with technologies like the CORI* Surgical System, and a strong clinical legacy. It's an ideal solution for surgeons looking to align with the principles of personalized care. The LEGION MedialStabilized TKS has demonstrated more than 20 years of clinical success, with the new medial stabilized insert adding a modern design to align with rapidly growing market trends. The LEGION Medial STabilized TKS is the latest addition to the LEGION portfolio supporting both the LEGION CONCELOC Cementless and LEGION Cemented Total Knee Systems. The medial stabilized insert for LEGION TKS is available in the US on a limited basis, with a full commercial release later in 2025. The system will also be introduced in Canada in 2026.お知らせ • May 15Smith+Nephew Announces A Comparative sNPWT Study of 10,000+ C-sections Shows PICO™ sNPWT Reduces Complications and Cuts Healthcare Costs by $728,000 Per 1,000 PatientsSmith+Nephew announced findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew’s leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and overall costs, compared to another sNPWT device (P=0.05). New survey: The real-life burden of C-section complications: A complementary survey of new mothers who have undergone C-sections highlighted the impact of SSCs on both mother and baby: Mothers with complications reported requiring hospital readmissions; Are 5 times more likely to describe their recovery as traumatic; Over half (55%) reported feeling depressed than those that reported no complications; Are 5.4 times more likely to be unable to breastfeed; Two in three mothers (66.3%) reported that their overall c-section recovery impacted their ability to bond with their baby. Real-world data shows the clinical and economic benefits of using PICO sNPWT in patients undergoing C-section procedures: The study used real-world evidence from the Premier PINC AI™ Healthcare Database to analyze outcomes from a geographically diverse mix of community hospitals, teaching hospitals and healthcare systems across the US. Notable findings include significant reductions with PICO sNPWT, compared to other sNPWT devices in the incidence of: Overall SSIs (p=0.018); Superficial SSIs (p=0.017); Wound dehiscence (p=0.005); Seroma formation(p=0.050). PICO sNPWT is proven to reduce the odds of surgical site infections (SSIs), which could facilitate early mother and baby bonding and positively impacts on the patient’s emotional wellbeing.お知らせ • May 02Smith & Nephew plc Maintains Earnings Guidance for the Full Year 2025Smith & Nephew plc maintained earnings guidance for the full year of 2025. For the period, the company guidance is unchanged: Underlying revenue growth expected to be around 5.0% (reported growth 5.4%), and significant trading profit margin expansion to between 19.0% and 20.0%. Continued higher cadence of product launches and clinical evidence contributing to growth. Unchanged outlook includes an expected net impact of $15 to $20 million from tariffs in 2025, based on announced measures, and mitigations.お知らせ • Apr 25Smith & Nephew plc Announces Steps Down of Bob White as an Independent Non-Executive Director, Effective 30 April 2025Smith & Nephew plc announced that Bob White has informed the Board that he will be stepping down as an Independent Non-Executive Director on 30 April 2025 and will not submit himself for re-election at the Company's Annual General Meeting to be held on 30 April 2025.お知らせ • Mar 11Smith & Nephew plc, Annual General Meeting, Apr 30, 2025Smith & Nephew plc, Annual General Meeting, Apr 30, 2025. Location: the smith nephew academy london, building 5, croxley park, hatters lane, wd18 8ye, watford United Kingdomお知らせ • Mar 10Smith & Nephew plc to Report First Half, 2025 Results on Jul 31, 2025Smith & Nephew plc announced that they will report first half, 2025 results on Jul 31, 2025お知らせ • Feb 25+ 1 more updateSmith & Nephew plc Recommends Final Dividend for 2024, Payable on May 28, 2025The Board of Smith & Nephew plc is recommending a Final Dividend of 23.1 cents per share (46.2 cents per ADS) (2023: 23.1 cents per share). Together with the Interim Dividend of 14.4 cents per share (28.8 cents per ADS), this will give a total distribution of 37.5 cents per share (75.0 cents per ADS), unchanged from 2023. Subject to confirmation at Annual General Meeting, the Final Dividend will be paid on 28 May 2025 to shareholders on the register at the close of business on 28 March 2025.お知らせ • Jan 14Smith & Nephew plc Announces Board and Committee ChangesSmith+Nephew announced that Sybella Stanley will join the Board as an independent Non-Executive Director with effect from 1 February 2025. Sybella will serve as a member of the Remuneration Committee and will succeed Angie Risley as Chair of the Remuneration Committee with effect from 30 June 2025. Sybella has worked for RELX Plc since 1997 and is currently Director of Corporate Finance. She retired in December 2024 from the Board of Tate & Lyle plc where she served for nine years as an Independent Non-Executive Director and was Chair of the Remuneration Committee. She served for nine years as an Independent Non-Executive Director of Merchants Trust PLC and as Senior Independent Director and Chair of the Remuneration Committee until her retirement in March 2024. She is also co-chair of the Development Board of Somerville College, Oxford.お知らせ • Dec 19Smith+Nephew Introduces CORIOGRAPH Pre-Op Planning and Modeling Services for Total Hip ArthroplastySmith+Nephew announced its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and modeling, enabling surgeons to make a patient-specific plan for the best possible outcome. The first procedures using CORIOGRAPH Pre- Op Planning and Modeling Services for Hip with RI.HIP solutions were recently completed by Dr. George Haidukewych, Surgeon in Chief and Academic Chairman at Orlando Health Jewett Orthopedic Institute in Orlando, FL. The CORI Surgical System offers proprietary tools and software across the full suite of procedure solutions to deliver a platform that is flexible and scalable across knee and hip joint arthroplasty indications. Built on 15+ years of clinical expertise and over 350,000 image-based hip and knee surgery plans, CORIOGRAPH Pre-op Planning and Modeling Services for hip is designed to optimize implant planning and personalization, including: Advanced modeling capabilities that utilize patient specific spinopelvic classification and pelvic tilt go beyond the mechanics of simple range-of-motion to simulate activities of daily living that help surgeons make decisions on optimal implant placement. Image-agnostic planning capabilities with 2D and/or 3D images to help personalize the end-to-end care specifically to the patient need. Can be used across the entire spectrum of Smith+Nephew hip implant solutions and technologies. CORIOGRAPH Pre-OP Planning and Modeling Services combined with RI.HIP solutions and the recently launched CADALYSTEM Primary Hip System, offer a complete solution for primary total hip arthroplasty.お知らせ • Nov 02Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025Smith & Nephew plc provided earnings guidance for the full year 2024 and for 2025. For the full year, company expected underlying revenue growth to be around 4.5% (previously 5.0% to 6.0%), primarily due to the impact of China headwind. For trading profit margin in 2024, company now expecting growth of up to 50bpscompared to last year's 17.5% (previously at least 18.0%), reflecting the reduced operating leverage from slower revenue growth. For 2025, given the updated 2024 outlook and, in particular, uncertainty around ongoing China headwinds, company now expects to expand trading profit margin significantly to between 19.0% and 20.0%, driven by the continued delivery of the 12-Point Plan improvements.お知らせ • Oct 31Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025Smith & Nephew plc announced that they will report fiscal year 2024 results on Feb 25, 2025お知らせ • Oct 02Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)Smith+Nephew announced that its LEGION Hinged Knee (HK) System is now available in the United States with proprietary OXINIUM (Oxidized Zirconium) implant technology that delivers the durability of metals, the wear resistance of ceramics, and corrosion resistance better than both. Part of the LEGION Total Knee (TK) System, the LEGION HK System is designed to provide a natural range of motion with medial pivot, lateral roll back, and screw home. Since 2011, the LEGION HK System has enabled surgeons to transition intraoperatively from a constrained revision knee implant to a CoCr-hinged assembly. The award winning OXINIUM Technology has demonstrated lower inflammatory response, superior wear resistance and reduced surface damage, and fewer signs of corrosion damage compared to cobalt chrome, ultimately helping to mitigate common risk factors associated with revision procedures. LEGION revision with proprietary OXINIUM Technology has established itself as the best performing bearing with the lowest risk of re-revision compared to the class average.お知らせ • Sep 27Smith+Nephew Announces Board and Committee ChangesSmith+Nephew announced that Angie Risley has been appointed as Senior Independent Director with effect from 1 October 2024. She will remain as Chair of the Remuneration Committee and a member of the Nomination & Governance Committee. Ms Risley succeeds Marc Owen who will remain the Chair of the Compliance & Culture Committee, and a member of the Audit and Nomination & Governance Committees.お知らせ • Aug 02+ 1 more updateSmith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024Smith & Nephew plc provided earnings guidance for the second half and reaffirms earnings guidance for the Year 2024. For the second half, The company expects higher revenue growth in the second half than the first. The guidance for 2024 is unchanged. The company's underlying revenue growth expected in the range of 5.0% to 6.0% (4.4% to 5.4% reported), and trading profit margin expected to be at least 18.0%.お知らせ • Jul 17Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip SystemSmith+Nephew announced it has received 510(k) clearance for its new CATALYSTEM Primary Hip System from the United States Food and Drug Administration. The system is designed to address the evolving demands of primary hip surgery including the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs). Advancements in primary hip arthroplasty include a shift to a shorter, proximally filling stem that is easier to prepare and insert using the direct anterior approach - a less invasive procedure that may enable improved range-of-motion and faster recovery for patients. This segment fits a diverse range of patient anatomies and is rapidly growing at a compound annual growth rate >10%. Building on the heritage of Smith+Nephew's clinically successful stem designs, the CATALYSTEM Primary Hip system was developed using global data sets across femoral morphologies to help deliver a precision fit. Featuring a triple-taper stem design with uniform proximal loading, the reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches. The CATALYSTEM Primary hip System also utilizes proprietary, patent-pending, ACCUBROACH Technology delivering proven reproducibility between broach and implant giving confidence in predictable and reproducible stem seating.お知らせ • Jul 05Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.) on July 4, 2024.Cevian Capital II GP Limited completed the acquisition of 5.02% stake in Smith & Nephew plc (LSE:SN.) on July 4, 2024.お知らせ • May 10Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024Smith & Nephew plc announced a final dividend of 23.1 US cents per ordinary share in respect of the year ended 31 December 2023 will be paid on 22 May 2024 to shareholders whose name appeared on the Register at the close of business on 2 April 2024. Those shareholders whose address on the Register is in the UK, and those who have validly elected to receive sterling dividends, will receive a dividend of 18.49 pence per share.お知らせ • May 01Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024Smith & Nephew plc announced that they will report first half, 2024 results on Aug 01, 2024お知らせ • Apr 02Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy SystemSmith+Nephew announced the launch of its RENASYS EDGE Negative Pressure Wound Therapy System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn, it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities. It is estimated that the annual financial burden of chronic wounds in the US is $33 billion, and affecting some 8.2 million people. The RENASYS EDGE System is designed for patients suffering from these wounds and living at home. Chronic wounds, including ulcers, have a huge impact on a patient’s life beyond just the pain and discomfort, with 68% often becoming self-conscious of their wound and many becoming isolated. The need to carry a bulky, noisy medical device that draws attention to their condition only increases this discomfort. Smith+Nephew is also announcing two new national distribution partners for the RENASYS EDGE System - SunMED Medical Solutions and First Nation Group. These new partnerships will enable Smith+Nephew to introduce this new, innovative technology to more patients on a national level and support its growing negative pressure wound therapy business. For clinicians, the RENASYS EDGE system is intuitive and easy-to-use. Its user-friendly interface gives step-by-step guidance on therapy application, and technical support is just one click away during set up with the near field communication feature on the system. Additionally, Smith+Nephew provides 24-hour customer support for patients and a clinical hotline.お知らせ • Mar 28+ 1 more updateSmith & Nephew plc Announces Board ChangesSmith & Nephew plc announced that John Rogers will join the Board as an Executive Director on 1 April 2024, succeeding Anne-Francoise Nesmes whose last day on the Board will be 31 March 2024.お知らせ • Mar 12Smith & Nephew plc, Annual General Meeting, May 01, 2024Smith & Nephew plc, Annual General Meeting, May 01, 2024, at 11:00 Coordinated Universal Time. Location: Smith+Nephew Academy London, Building 5, Croxley Park, Hatters Lane, Watford, WD18 8YE Watford, London United Kingdomお知らせ • Feb 29+ 1 more updateSmith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024Smith & Nephew plc is recommending a Final Dividend of 23.1¢ per share (46.2¢ per ADS) (2022: 23.1¢ per share). Together with the Interim Dividend of 14.4¢ per share (28.8¢ per ADS), this will give a total distribution of 37.5¢ per share (75.0¢ per ADS), unchanged from 2022. Subject to confirmation at Annual General Meeting, the Final Dividend will be paid on May 22, 2024 to shareholders on the register at the close of business on April 2, 2024.お知らせ • Feb 13+ 1 more updateSmith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual MeetingSmith+Nephew announced full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025. Developed to restore patients' range-of-motion2-5 and help minimize arthritic shoulder pain, the AETOS Shoulder System features the Meta Stem which is designed for stability with metaphyseal fixation and an inlay collar, bone preservation, and to maintain patient anatomy. Indicated for both anatomic and reverse total shoulder arthroplasty, the AETOS Shoulders System offers a compact yet comprehensive portfolio of solutions that enhance the surgical experience by enabling intraoperative flexibility. With fewer steps for conversion and fewer instruments for primary anatomic and reverse, the system is designed to simplify the operating room flow. This also allows for an efficient solution, particularly of value in an Ambulatory Service Center (ASC) environment where sterilization and space limitations may be of concern. Fast turnaround time from image upload to planning. An optional 3D-printed glenoid guide, designed with the patented coracoid clip for stability, provides a reliable and accurate method to execute the surgical plan through conventional surgical techniques. The AETOS Shoulder System received 510(k) clearance from the United States Food and Drug Administration in June of 2023. It is the latest addition to Smith+Nephew's expanding Upper Extremity portfolio and complements market-leading Sports Medicine shoulder repair solutions to enable biological healing.お知らせ • Jan 11+ 1 more updateSmith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled TrialSmith & Nephew plc announced standout results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online in Arthroscopy in December, the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant had better tendon healing compared to the standard of care, as evidenced by: A significantly lower re-tear rate (8.3 vs 25.8%; p=0.01), A three times lower risk of re-tear (RR=0.32; 95% CI:0.13–0.83) and No difference in the number of serious or minor complications. The blinded, multi-centre RCT compared the healing rate of full-thickness rotator cuff tears repaired with and without augmentation with the REGENETEN Bioinductive Implant. In total, 124 patients with reparable medium and large (1–4cm) full-thickness posterosuperior rotator cuff tears were randomized to receive either an arthroscopic transosseous equivalent double-row rotator cuff repair or the same repair augmented with the REGENETEN Bioinductive Implant. With more than 100,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for more than 1 million people having surgery for a rotator cuff tear each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.お知らせ • Dec 07Smith+Nephew Announces Board ChangesSmith+Nephew announced that Rick Medlock has notified the Board of his decision not to submit himself for re-election as a Non-Executive Director at the next annual general meeting of the Company. Jez Maiden, Non-Executive Director, will be appointed Chair of the Audit Committee with effect from 1 March 2024. The Board would like to thank Rick for his commitment and contribution to the Board and the Company and to congratulate Jez on his new appointment. joined the Board in 2023 and has extensive financial experience across a diverse range of industries and sectors. Jez was Chief Financial Officer of 5 UK-listed companies over a period of 24 years and has served as a Non-Executive Director on boards of companies addressing strategic and operational challenges across a number of different industries, including life-sciences and healthcare. He was previously Chair of the Audit Committee at Synthomer PLC and PZ Cussons plc. Current external appointments; Senior Independent Director, Travis Perkins plc. Non-Executive Director and member of the Audit Committee at Intertek Group plc. Jez retired in 2023 as Group Finance Director at Croda International plc, the FTSE 100 global speciality chemicals company, and previously held similar roles at National Express Group plc and Northern Foods Limited. He has served as the Senior Independent Director at Synthomer PLC and at both PZ Cussons plc and Synthomer PLC he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants.お知らせ • Nov 24Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million on November 22, 2023. Under the terms of transaction, initial cash consideration of $180 million at closing and up to a further $150 million contingent on financial performance will be paid. The acquisition will be financed from existing cash and debt facilities. All CartiHeal employees are expected to transfer to Smith+Nephew. The transaction is expected to close in the first quarter of 2024.お知らせ • Nov 04Smith & Nephew plc Provides Earning Guidance for Full Year 2023Smith & Nephew plc provided earning guidance for full year 2023. For the period, underlying revenue growth currently expected to be towards the higher end of guided range of 6.0% to 7.0% and trading profit margin now expected to be around 17.5%, reflecting headwinds from china.お知らせ • Nov 02Smith & Nephew plc Announces Appointment of John Rogers as CFOSmith & Nephew plc announced that John Rogers will succeed Anne-Françoise Nesmes as Chief Financial Officer. He will join the company as Chief Financial Officer-designate on 1 December 2023 and, following a period of induction, will join the Board as Chief Financial Officer in the first quarter of 2024. Anne-Françoise's intention to step down as Chief Financial Officer was announced on 3 August 2023, and she has agreed to remain on the Board to finalise the 2023 Annual Report and Accounts and support an effective transition. John has extensive financial and commercial leadership experience across a range of sectors and on a global basis, as well as a track record of delivering complex international transformation programmes. He has served as the Chief Financial Officer of two FTSE-100 companies. He was most recently Chief Financial Officer at WPP plc where he successfully led the implementation of their global transformation programme. Prior to WPP, John was Chief Financial Officer at J Sainsbury plc and also served as Chief Executive Officer ofArgos, Habitat and Sainsbury's clothing and general merchandise businesses, where he led a major digitisation programme, driving increased market share and double-digit profit growth.お知らせ • Oct 22Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023Smith & Nephew plc announced on 3 August 2023, an interim dividend for 2023 of 14.4 US cents per ordinary share will be paid on 1 November 2023 to shareholders whose names appeared on the Register at the close of business on 6 October 2023. Those shareholders whose address on the Register is in the UK, and those who have validly elected to receive sterling dividends, will receive a dividend of 11.89 pence per share.お知らせ • Sep 14Smith & Nephew plc Announces Board and Committee ChangesSmith+Nephew announced that Jeremy (Jez) Maiden and Simon Lowth will be joining the Board as independent Non-Executive Directors. Jez joins and will serve as a member of the Audit Committee and Remuneration Committee. Simon will join on 1 January 2024 and will serve as a member of the Audit Committee and Nomination & Governance Committee. Additionally,Rupert Soames will, as planned,assume the role as Chair of the Board on 15 September, in succession to Roberto Quarta. Rupert has also been appointed as Chair of the Nomination & Governance Committee and will continue to serve on the Remuneration Committee. Jez Maiden has extensive global financial experience across a diverse range of industries and sectors. He retired earlier this year as Group Finance Director at Croda International, the FTSE-100 global speciality chemicals company, and before that held similar roles at National Express Group and Northern Foods. He is currently Senior Independent Director at Travis Perkins plc and a Non-Executive Director and member of the Audit Committee at Intertek Group plc. Previously, he served as the Senior Independent Director at Synthomer and at both PZ Cussons and Synthomer he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants. Simon Lowthhas deep experience in finance, accounting, risk, corporate strategy as well as mergers and acquisitions.He currently serves as Group Chief Financial officer of BT Group, a role he has held since 2016 and previously performed the same role at BG Group, AstraZeneca and Scottish Power.Before joining Scottish Power, he led the Industrial Practice of McKinsey in the UK and has a background in engineering. He previously served as a Non-Executive Director on the Board of Standard Chartered. He currently holds no additional external appointments.お知らせ • Aug 04Smith & Nephew plc Increases Revenue Guidance for 2023Smith & Nephew plc announced full year guidance for 2023. For the year, the company expects revenue growth guidance of 6.0% to 7.0% (previously 5.0% to 6.0%).お知らせ • Aug 03Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial OfficerSmith & Nephew plc announced that Anne-Françoise Nesmes has informed the Board of her intention to step down as Chief Financial Officer during the second quarter of 2024, on a date to be agreed. The Board has initiated an external search for her successor.お知らせ • Jun 13Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder SystemSmith+Nephew announced that it has received 510(k) clearance from the United States Food and Drug Administration for its AETOS Shoulder System. Designed to restore patients' range-of-motion1-4 and help minimize arthritic shoulder pain. Features the AETOS Meta Stem - designed to maximize stability, preserve bone, and maintain patient anatomy. Indicated for both anatomic and reverse total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025. For healthcare professionals, the AETOS Shoulder System offers a compact yet comprehensive portfolio of solutions that enhance the surgical experience by enabling intraoperative flexibility. With fewer steps for conversion and fewer instruments for primary anatomic and reverse, the system is designed to simplify the operating room flow. The AETOS Shoulder System is the latest solution in Smith+Nephew's expanding Upper Extremity portfolio and complements market leading Sports Medicine shoulder repair and biologics solutions.お知らせ • Feb 17+ 1 more updateSmith & Nephew plc, Annual General Meeting, Apr 26, 2023Smith & Nephew plc, Annual General Meeting, Apr 26, 2023. Agenda: To elect independent non-executive director.お知らせ • Nov 04Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023Smith & Nephew plc announced that they will report fiscal year 2022 results on Feb 21, 2023お知らせ • Sep 13+ 1 more updateSmith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023Smith & Nephew plc announced that they will report Q2, 2023 results on Aug 03, 2023株主還元SNNU.FUS Medical EquipmentUS 市場7D0%-3.5%1.3%1Y4.9%-21.9%27.7%株主還元を見る業界別リターン: SNNU.F過去 1 年間で-19.6 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: SNNU.Fは、過去 1 年間で26.4 % のリターンを上げたUS市場を下回りました。価格変動Is SNNU.F's price volatile compared to industry and market?SNNU.F volatilitySNNU.F Average Weekly Movementn/aMedical Equipment Industry Average Movement8.5%Market Average Movement7.2%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.0%安定した株価: SNNU.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のSNNU.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト185616,988Deepak Nathwww.smith-nephew.comスミス・アンド・ネフュー社は、その子会社とともに、英国、米国、および国際的な医療機器およびサービスの開発、製造、マーケティング、販売を行っている。事業セグメントは3つ：整形外科、スポーツ医学・耳鼻咽喉科、先進創傷管理の3部門。同社は、人工膝関節置換術用の膝インプラント製品、再置換術用の股関節インプラント製品、重度の骨折の安定化や変形矯正術に使用される内・外装器具を含む外傷・四肢製品、その他の再建製品を提供している。また、肩、膝、股関節、小関節の軟部組織損傷や退行性疾患の治療だけでなく、低侵襲手術を行うための器具、技術、インプラントからなるスポーツ医学関節修復製品も提供している。さらに、関節内の可視化を補助するための手術アクセス用流体管理装置、カメラ、デジタル画像キャプチャ、スコープ、光源、モニター、損傷した組織を除去するための高周波、電気機械的、機械的組織切除装置、手用器具、耳、鼻、喉のソリューションからなる関節鏡を可能にする技術も提供している。さらに、急性・慢性創傷、下腿潰瘍、糖尿病性潰瘍、褥瘡、熱傷、術後創傷の治療と予防のための高度創傷ケア製品、デブリードマンや真皮修復・再生のための生物製剤やその他の生物活性技術、皮膚、骨移植片、関節軟骨代替物などの再生医療製品などの高度創傷生物活性剤、従来型・単回使用の陰圧創傷治療や水手術システムなどの高度創傷器具を提供している。同社は医療提供者にサービスを提供している。スミス・アンド・ネフューは1856年に設立され、イギリスのワトフォードに本社を置いている。もっと見るSmith & Nephew plc 基礎のまとめSmith & Nephew の収益と売上を時価総額と比較するとどうか。SNNU.F 基礎統計学時価総額US$13.02b収益（TTM）US$625.00m売上高(TTM)US$6.16b20.8xPER（株価収益率2.1xP/SレシオSNNU.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SNNU.F 損益計算書（TTM）収益US$6.16b売上原価US$1.96b売上総利益US$4.21bその他の費用US$3.58b収益US$625.00m直近の収益報告Dec 31, 2025次回決算日Aug 04, 2026一株当たり利益（EPS）0.73グロス・マージン68.25%純利益率10.14%有利子負債／自己資本比率58.8%SNNU.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.6%現在の配当利回り54%配当性向SNNU.F 配当は確実ですか？SNNU.F 配当履歴とベンチマークを見るSNNU.F 、いつまでに購入すれば配当金を受け取れますか？Smith & Nephew 配当日配当落ち日Mar 26 2026配当支払日May 27 2026配当落ちまでの日数63 days配当支払日までの日数1 daySNNU.F 配当は確実ですか？SNNU.F 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 03:09終値2026/05/19 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Smith & Nephew plc 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。34 アナリスト機関Sally TaylorBarclaysHassan Al-WakeelBarclaysSamuel EnglandBerenberg31 その他のアナリストを表示
お知らせ • May 07+ 1 more updateSmith & Nephew plc (LSE:SN.) announces an Equity Buyback for $500 million worth of its shares.Smith & Nephew plc (LSE:SN.) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its shares. The program will be financed from free cash flow and existing cash balances. The program will be valid for 12 months.
お知らせ • May 06Smith & Nephew plc to Report Q2, 2026 Results on Aug 04, 2026Smith & Nephew plc announced that they will report Q2, 2026 results on Aug 04, 2026
お知らせ • Apr 22SMITH & NEPHEW PLC Announces New Data for Cartiheal Agili-C Cartilage Repair ImplantSMITH & NEPHEW PLC announced further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care for all time points out to 60 months. Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year period. Patients treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport and recreation at 2, 4 and 5-years. Equal clinical outcomes were found in OA and non-OA patients receiving the CARTIHEAL Implant. Smith+Nephew's FDA-approved CARTIHEAL Implant is revolutionizing the cartilage repair landscape with the implant's broad indication allowing physicians to treat patients who previously may not have had access. The implant recently received a Category I Current Procedural Terminology (CPT) code for procedures that will go into effect on January 1, 2027.
お知らせ • Apr 10Smith+Nephew Announces Significant Outcome Improvements for Regeneten Bioinductive Implant in Partial-Thickness Rotator Cuff TearsSmith+Nephew announced compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the REGENETEN Bioinductive Implant in isolation. Compared with a traditional suture anchor repair, early recovery time was halved for patients returning to daily activities such as: Driving: 2.3 vs 5.1 weeks, Office work: 1.7 vs 3.6 weeks (p=0.009), Moderate-intensity household chores: 3.8 vs 8.4 weeks. The study, recently published in the Orthopaedic Journal of Sports Medicine, also concluded that REGENETEN Implant patients enjoyed a better quality of life at 6 weeks and 3 months, and high rates of tendon healing at 1 year, comparable to suture anchor-based repairs. This is the third RCT demonstrating that the REGENETEN Bioinductive Implant improves outcomes versus traditional rotator cuff repair techniques. With more than 250,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for thousands of patients with rotator cuff injuries every year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs. This evidence follows the recent revision to the American Academy of Orthopaedic Surgeons Clinical Practice Guideline on the ‘Management of Rotator Cuff Injuries’ which highlights the value of bioinductive implants in rotator cuff repair based on an independent analysis of studies. The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair.
お知らせ • Mar 17Smith & Nephew plc, Annual General Meeting, May 06, 2026Smith & Nephew plc, Annual General Meeting, May 06, 2026. Location: the smith nephew academy london, building 5, croxley park, hatters lane, wd18 8ye., watford 8ye., watford United Kingdom
お知らせ • Mar 11Smith+Nephew Launches Allevyn Complete Care Foam DressingSmith+Nephew recently announced the launch of ALLEVYN COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence. ALLEVYN COMPLETE CARE Dressing has a unique five-layer construction with distinct mode of action technologies targeted towards both wound management and pressure injury prevention. Minimising leakage and disruption by fewer dressing changes, and protecting vulnerable skin are essential to achieving this goal. Global estimates suggest that up to one in 50 adults are affected by chronic wounds in their lifetime, facing delayed healing and complications that impact daily life. Studies report up to one in 10 hospitalised patients are affected by pressure injuries, with hospital-acquired pressure injuries associated with an average of 9.5 additional days of hospital stay. Pressure injuries and chronic wounds continue to place a significant burden on the broader healthcare system. ALLEVYN COMPLETE CARE Dressing’s proprietary technologies have advanced capabilities that are designed to help clinicians care with confidence. The dressing was developed to address the needs of both wound management and pressure injury prevention, informed by collaboration with healthcare professionals and patients worldwide. It is proven to lock in significantly more exudate than other foam dressings while keeping over 99% of bacteria away from the wound bed. This minimises leakage, enables longer wear times for undisturbed healing, and has potential to release over 10% of valuable nursing time. Unbonded sliding layers within the dressing absorb up to 93% of mechanical energy, helping to reduce the risk of pressure injury by over 65%. ALLEVYN COMPLETE CARE Dressing’s unbonded multilayer structure delivers a distinct mode of action that helps dissipate shear forces before they reach the skin and underlying soft tissues. This pioneering technology protects soft tissue and minimises the risk of developing a pressure injury. ALLEVYN COMPLETE CARE Dressing is available in five different shapes and a variety of sizes to meet a diverse range of wound care needs. Initially available in the US, the dressing will be launching in many European and other international markets in 2026 as the company continue to support patients’ unique needs, and shape what’s possible in wound care.
お知らせ • May 07+ 1 more updateSmith & Nephew plc (LSE:SN.) announces an Equity Buyback for $500 million worth of its shares.Smith & Nephew plc (LSE:SN.) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its shares. The program will be financed from free cash flow and existing cash balances. The program will be valid for 12 months.
お知らせ • May 06Smith & Nephew plc to Report Q2, 2026 Results on Aug 04, 2026Smith & Nephew plc announced that they will report Q2, 2026 results on Aug 04, 2026
お知らせ • Apr 22SMITH & NEPHEW PLC Announces New Data for Cartiheal Agili-C Cartilage Repair ImplantSMITH & NEPHEW PLC announced further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care for all time points out to 60 months. Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year period. Patients treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport and recreation at 2, 4 and 5-years. Equal clinical outcomes were found in OA and non-OA patients receiving the CARTIHEAL Implant. Smith+Nephew's FDA-approved CARTIHEAL Implant is revolutionizing the cartilage repair landscape with the implant's broad indication allowing physicians to treat patients who previously may not have had access. The implant recently received a Category I Current Procedural Terminology (CPT) code for procedures that will go into effect on January 1, 2027.
お知らせ • Apr 10Smith+Nephew Announces Significant Outcome Improvements for Regeneten Bioinductive Implant in Partial-Thickness Rotator Cuff TearsSmith+Nephew announced compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the REGENETEN Bioinductive Implant in isolation. Compared with a traditional suture anchor repair, early recovery time was halved for patients returning to daily activities such as: Driving: 2.3 vs 5.1 weeks, Office work: 1.7 vs 3.6 weeks (p=0.009), Moderate-intensity household chores: 3.8 vs 8.4 weeks. The study, recently published in the Orthopaedic Journal of Sports Medicine, also concluded that REGENETEN Implant patients enjoyed a better quality of life at 6 weeks and 3 months, and high rates of tendon healing at 1 year, comparable to suture anchor-based repairs. This is the third RCT demonstrating that the REGENETEN Bioinductive Implant improves outcomes versus traditional rotator cuff repair techniques. With more than 250,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for thousands of patients with rotator cuff injuries every year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs. This evidence follows the recent revision to the American Academy of Orthopaedic Surgeons Clinical Practice Guideline on the ‘Management of Rotator Cuff Injuries’ which highlights the value of bioinductive implants in rotator cuff repair based on an independent analysis of studies. The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair.
お知らせ • Mar 17Smith & Nephew plc, Annual General Meeting, May 06, 2026Smith & Nephew plc, Annual General Meeting, May 06, 2026. Location: the smith nephew academy london, building 5, croxley park, hatters lane, wd18 8ye., watford 8ye., watford United Kingdom
お知らせ • Mar 11Smith+Nephew Launches Allevyn Complete Care Foam DressingSmith+Nephew recently announced the launch of ALLEVYN COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence. ALLEVYN COMPLETE CARE Dressing has a unique five-layer construction with distinct mode of action technologies targeted towards both wound management and pressure injury prevention. Minimising leakage and disruption by fewer dressing changes, and protecting vulnerable skin are essential to achieving this goal. Global estimates suggest that up to one in 50 adults are affected by chronic wounds in their lifetime, facing delayed healing and complications that impact daily life. Studies report up to one in 10 hospitalised patients are affected by pressure injuries, with hospital-acquired pressure injuries associated with an average of 9.5 additional days of hospital stay. Pressure injuries and chronic wounds continue to place a significant burden on the broader healthcare system. ALLEVYN COMPLETE CARE Dressing’s proprietary technologies have advanced capabilities that are designed to help clinicians care with confidence. The dressing was developed to address the needs of both wound management and pressure injury prevention, informed by collaboration with healthcare professionals and patients worldwide. It is proven to lock in significantly more exudate than other foam dressings while keeping over 99% of bacteria away from the wound bed. This minimises leakage, enables longer wear times for undisturbed healing, and has potential to release over 10% of valuable nursing time. Unbonded sliding layers within the dressing absorb up to 93% of mechanical energy, helping to reduce the risk of pressure injury by over 65%. ALLEVYN COMPLETE CARE Dressing’s unbonded multilayer structure delivers a distinct mode of action that helps dissipate shear forces before they reach the skin and underlying soft tissues. This pioneering technology protects soft tissue and minimises the risk of developing a pressure injury. ALLEVYN COMPLETE CARE Dressing is available in five different shapes and a variety of sizes to meet a diverse range of wound care needs. Initially available in the US, the dressing will be launching in many European and other international markets in 2026 as the company continue to support patients’ unique needs, and shape what’s possible in wound care.
お知らせ • Mar 04Smith+Nephew to Showcase Advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma Technologies During AAOS 2026Smith+Nephew announced it will feature handheld robotics and digital solutions for hip, knee and shoulder in addition to innovative trauma and extremities products during the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. Some of the company’s latest Orthopaedics advancements and highlighted technologies include: Handheld Robotics: Optimizing and Personalizing Surgery. As the leader in handheld robotics, the CORI? Surgical System delivers a digital surgery ecosystem–spanning solutions from advanced pre-operative planning and a connected post-operative data management solution. The entire robotics ecosystem is designed to amplify the surgeon experience and expertise and has shown improvements in accuracy and patient outcomes in joint arthroplasty. Smith+Nephew’s CORIOGRAPH? Pre-Op Planning and Modeling Services enables optimization of handheld robotic knee and shoulder arthroplasty and computer guided hip – further personalizing surgery for both surgeons and their patients. CORIOGRAPH Pre-Op Planning and Modeling Services + CORI Surgical System supports several image modalities - allowing for a new dimension of pre-operative planning for each individual patient - and supporting the intra-operative surgical workflow. In the booth at AAOS, Smith+Nephew will have a motion capture lounge demonstrating how 3-D modeling of patient motion is important in planning implant position and advanced simulated activities of daily living. CORI XT is required for shoulder application. CORI SHOULDER Robotic Shoulder Arthroplasty with the AETOS? Shoulder System: Differentiated Technology for Personalized Care. In the fast-growing shoulder market, the CORI SHOULDER Platform is well positioned to meet the unmet needs of surgeons who demand both accuracy and procedural efficiency. The system is specifically optimized for use with the AETOS Shoulder System. It features the CORI Handheld Robotic Platform technology and supports robotic preparation of both humeral and glenoid execution for shoulder arthroplasty. Smith+Nephew advances robotic shoulder arthroplasty with a complete, handheld solution that supports seamless integration and workflow efficiencies for shoulder arthroplasty. The procedure represents a significant leap forward in the shoulder arthroplasty space, perfectly suited for the constraints of the anatomy and supported by a portable footprint for flexibility in the hospital or ASC. Last week, the first ever CORI SHOULDER Robotic Shoulder Arthroplasty cases were completed, performed by a surgical team at Duke Health led by Dr. Christopher Klifto. To learn more, please visit the CORI SHOULDER website or see a live demo of CORI SHOULDER Robotic Shoulder Arthroplasty at AAOS in Booth #839. Advanced Implant Science. Get the latest clinical data and insights on our flagship implant options for hip, knee and shoulder arthroplasty including recent additions to our portfolio such as LEGION? Total Knee Medial Stabilized System, CATALYSTEM? Primary Hip System and the AETOS Shoulder System stemless option. Trauma Advancements. From reduction to fixation, the EVOS? LARGE & PERIPROSTHETIC Plating System has evolved to give surgeons stability and flexibility with one screw design for threaded locking, and variable-angle locking and compatibility with the EVOS Cabling System. We will also be expanding the EVOS portfolio this year with the launch of the EVOS PELVIC System. TRIGEN? MAX Tibia Nailing System is the only system to give trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options. Come visit Smith+Nephew at Booth #839 and hear about the expansion of TRIGEN MAX Tibia this year. Smith+Nephew has also recently signed distribution agreements with SI-BONE, focused on their innovative iFuse TORQ portfolio for pelvic fractures and RMR Ortho for the A’TOMIC™ Nitinol Fixation System, a compression fixation option for trauma cases. At the ASC suite, Smith+Nephew will provide customers with a preview of our expanded enterprise ASC offering—an end-to-end solution designed to support both de novo ASC development and the modernization of existing facilities. This comprehensive model enables customers to finance, design, build, equip, and optimize their centers through one coordinated, streamlined pathway. Through new strategic partnerships with Brasfield & Gorrie, Ghafari Associates, Unity Health Centers, and STERIS, we are bringing best-in-class expertise and technologies together into a single, aligned delivery model—helping customers accelerate timelines, reduce complexity, and drive operational performance from day one.
お知らせ • Mar 03+ 1 more updateSmith & Nephew plc Recommends Final Dividend for 2025, Payable on May 27, 2026Smith & Nephew plc announced the Board is recommending a Final Dividend of 24.1 US cents per share for 2025(48.2 US cents per ADS) (2024: 23.1 US cents per share). Together with the Interim Dividend of 15.0 US cents per share (30.0 US cents per ADS) (2024: 14.4 US cents), this will give a total distribution of 39.1 US cents per share (78.2 US cents per ADS), a 4.3% increase from 2024. The 38% payout ratio is in line with the 35-40% indicated in our capital allocation framework. The dividend will be paid, subject to shareholder approval, on 27 May 2026 to shareholders whose names appear on the Register of Members on 27 March 2026. The sterling equivalent per ordinary share will be set following the record date. The ex-dividend date is 26 March 2026 and the final day for currency and dividend reinvestment plan (‘DRIP’) elections is 5 May 2026.
お知らせ • Jan 22Smith & Nephew plc (LSE:SN.) completed the acquisition of Integrity Orthopaedics, Inc.Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million on January 12, 2026. The transaction is expected to close by end of January 2026. Pran Jha, Joe Michaels, Danielle Haikal, Hannah Ellis, Kathy Jara, McKenna Chadwick, Parker Whitlow, Lauren Grau, Dina Kang, Patrick Donaldson, Lauren Gallagher, Amanda Casanueva, Nicholas Carballo, Cathryn Le Regulski, Kristina Daisak, Torrey Cope, Kelly Cho, Lauren Limbach, Elizabeth Hardcastle, Melody Mostow, Gabrielle Feliciani, Ash Nagdev, Sasha Hondagneu-Messner, Liz McCloy, Brandon Bryer, Suresh Advani and George Chen of Sidley Austin LLP acted as legal advisors for Smith & Nephew plc. Smith & Nephew plc (LSE:SN.) completed the acquisition of Integrity Orthopaedics, Inc. on January 21, 2026.
お知らせ • Jan 13Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million.Smith & Nephew plc (LSE:SN.) agreed to acquire Integrity Orthopaedics, Inc. for $450 million on January 12, 2026. The transaction is expected to close by end of January 2026.
お知らせ • Nov 07+ 1 more updateSmith & Nephew plc Maintains Earnings Guidance for the Full Year of 2025Smith & Nephew plc maintained earnings guidance for the full year of 2025. For the year, the company expects trading profit margin to expand to between 19.0% and 20.0%, a significant step-up year-on-year (2024: 18.1%), outlook includes an expected net impact of $15 million to $20 million from tariffs in 2025, based on announced measures, and mitigations, as previously stated.
お知らせ • Nov 06Smith & Nephew plc to Report Fiscal Year 2025 Results on Mar 02, 2026Smith & Nephew plc announced that they will report fiscal year 2025 results on Mar 02, 2026
お知らせ • Oct 28Smith+Nephew Announces Findings from A Newly Published, First-Of-Its-Kind comparative Study of Single-Use Negative Pressure Wound Therapy Devices inorthopedic and Cardiovascular SurgerySmith+Nephew announced findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery. Analyzing real-world data from over 22,000 patients in the Premier PINC AI™? Healthcare Database, the analysis reveals that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces the risk of wound dehiscence, hospital length of stay (LoS), and overall healthcare costs compared to the PrevenaTM -125 mmHg sNPWT device. An estimated 313 million surgical procedures are performed worldwide each year, with the number continuing to rise. In the United States, surgical site infections (SSIs) occur in approximately 2% to 4% of patients undergoing inpatient procedures. In relation to PrevenaTM sNPWT (-125mmHg), use of PICO sNPT (-80mmHg) resulted in the following key study findings: Cardiovascular Surgery (5,000+ patients) 57.8% relative reduction in wound dehiscence risk (P 9.1% relative reduction in LoS (6.33 days vs. 6.86 days) (P 10.34% relative reduction in admission-related costs and 13% lower expenditures within three months post-surgery (P Orthopedic Surgery (17,000+ patients) 63.9% relative reduction in wound deHiscence incidence (p 29.7% relative reduction in LoS(2.43 days vs. 3.10 days) (pp 21.95% relative reduction in mean index admission cost and a 21% reduction at 30- and 90-day post-surgery. These findings complement the growing evidence supporting prophylactic use of incisional negative pressure wound therapy (iNPWT) across surgery. A recent meta-analysis presented at the International Consensus Meeting 2025 concluded that "The use of iNPWT is recommended to minimize the risk of SSI in adult patients with primarily closed surgical incisions after lower extremity/acetabular fracture surgery and joint arthroplasty of the hip and knee." These findings are aligned with the global recommendations including NICE4, WHO5 and the ACS/SIS6 guidelines, all of which recommend the use of iNPWT for the purpose of reducing the risk of SSI for at risk patients.
お知らせ • Sep 13Smith+Nephew Unveils Major Clinical Evidence and Patient Access Updates for its REGENETEN Bioindictive ImplantSmith+Nephew announced new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to help surgeons treat more patients who suffer from rotator cuff tears and other tendon and extra-articular ligament injuries throughout the body: AAOS Clinical Practice Guideline (CPG) on the Management of Rotator Cuff Injuries: For the first time, recent updates to the American Academy of Orthopaedic Surgeons (AAOS) CPG on the Management of Rotator Cuff Injuries highlight the value of bioinductive implants in rotator cuff repair, based on independent analysis of studies: AAOS CPGs provide evidence-based recommendations for current orthopaedic diagnostic, treatment, and postoperative procedures; Analyzing RCTs for bioinductive implants, AAOS have issued a StrongRecommendation that: ‘The use of bioinductive tendon implants to augment rotator cuff repair, or as an alternative to standard repair, can lead to lower re-tear rates and better patient reported outcomes.’ Randomized Controlled Trial (RCT) Results: Two-year results of the MALLAMANGUITO RCT from Dr. Miguel A. Ruiz Ibán and colleagues demonstrated a sustained 65% relative reduction in re-tear rates when using the REGENETEN Bioinductive Implant to augment repair of full-thickness rotator cuff tears: Two-year re-tear rates were 12.3% (7/57) with the REGENETEN Implant vs. 35.1% (20/57) with standard repair (p=0.004).These results build on previously reported 1-year results which have already made a significant impact in supporting patient access and adoption. Extra-articular Ligaments: For the first time, Smith+Nephew is able to market the REGENETEN Bioinductive Implant for extra-articular ligament injuries in the US. This new indication expansion offers opportunities to reach more patients with soft tissue injuries throughout the body. It will initially focus on hip capsule repair with abundant opportunities for future expansions in other extra-articular ligament repairs.With more than 150,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for the more than 1 million people having tendon or extra-articular ligament repair each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tissue to biologically augment repairs and support natural healing processes. The REGENETEN Bioinductive Implant is part of Smith+Nephew’s comprehensive Advanced Healing Solutions portfolio – redefining biological healing in rotator cuff repair.
お知らせ • Sep 03Smith+Nephew Extends Advanced Wound Bioactives Portfolio with US Launch of Centrio Platelet-Rich-Plasma SystemSmith+Nephew announced the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment. CENTRIO PRP System can help manage chronic exuding wounds including but not limited to diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, and tunnelling wounds. Due to a National Coverage Determination (NCD) made effective April 2021, autologous PRP for the treatment of chronic non-healing wounds for diabetic patients has CMS coverage, when prepared by devices whose indications include the management of exuding cutaneous wounds, such as diabetic ulcers.1 The CENTRIO PRP System is designed for point-of-care use in both hospital and physician office settings and the gel can be tailored to fit wound shape, depth, and stage with a single draw of a patient's blood. CENTRIO PRP system has demonstrated efficacy in two randomized, controlled clinical trials2,3, making it a strong fit in Smith+Nephew's clinically proven portfolio. The CENTRIO PRP system will premiere at the Smith+Nephew booth during the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas, Nevada from September 3-6. Smith+Nephew entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc., a commercial stage medical device company pioneering biodynamic therapies, to market the CENTRIO PRP System in the United States.
お知らせ • Aug 28Smith & Nephew plc Announces Dr Garheng Kong Will Join as an Independent Non-Executive Director and Member of the Audit Committee, Effective September 1, 2025Smith & Nephew plc announced that Dr Garheng Kong will join the Board as an independent Non-Executive Director and a member of the Audit Committee with effect from 1 September 2025. Garheng is currently managing partner and co-founder of HealthQuest Capital. He also serves as lead independent director of Laboratory Corporation of America (LabCorp) and a non-executive director of Xeris Biopharma Holdings Inc, Lunit Inc. and IKS Health. Garheng was previously managing general partner of Sofinnova Investments Inc. and served as a non-executive director of Venus Concept, Inc, Alimera Sciencesand Avedro Inc. and as chair of Histogenics Corporation.
お知らせ • Jul 07Smith+Nephew Announces the Release of Its Q-Fix Knotless All-Suture Anchor for Soft Tissue-To-Bearing Indications Across Multiple Joint Spaces Including Shoulder, Hip, Hip, and Foot & AnkleSmith+Nephew announced the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including shoulder, Hip, and Foot & Ankle. Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices, the new Q-FIX KNOTless All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS all-Suture Anchor aims to set a new benchmark for fixation strength and offer surgeons a reason to reassess their joint repair approach, including: Market-leading strength in all-suture anchor fixation1-5 and ultra-low displacement1,6-10 Consistent deployment4,11,12, Best-in-class soft tissue security with suture lock mechanism. Streamlined suture shuttling5, Market-leading biomechanical performance,+ 1-4,6,7 with the lowest displacement during cyclic loading++1,3,6,7 The Q-FIX KNOTless all-Sutures Anchor offers a versatile range of suture options that include both single-loaded MinITAPE Suture Tape - which has a low profile and coreless design to offer a lower and more evenly distributed level of pressure13,14 or ULTRABRAID #2 Suture that is 20% stronger than its nearest competitor.
お知らせ • Jun 24+ 1 more updateSmith+Nephew Announces the Launch of Its New Trigen Max Tibial Nailing System for Stable and Institutional Fulfillment of the Tibia, Including the ShaftSmith+Nephew announced the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw corridors, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options. The TRIGEN MAX TibiaNailing System aims to streamline operative procedures and provide efficiency through surgeon-centered design of components and instrumentation, including: Two-piecemodular drop system to help when using ancillary instruments and aid visualization. 12.5mm channel reamer for the tibia which is designed to preserve the integrity of the entry point and provide soft tissue protection. 5.0mm Lag Screws that compress the fracture in one screw insertion step, creating a streamlined workflow. The new TRIGEN MAX Tibial Nailing System is poised to be the next product setting the standard of care and performance for intramedullary nails. The TRIGEN MAXibia Nailing System is currently available in the United States only.
お知らせ • Jun 13Smith & Nephew plc Appoints David King as an Independent Non-Executive Director and Member of the Compliance & Culture and the Remuneration Committees, Effective 1 July 2025Smith & Nephew plc announced that David King will join the Board as an independent Non-Executive Director with effect from 1 July 2025. David will serve as a member of the Compliance & Culture and the Remuneration Committees. David is currently CEO, executive director and chair of Fortis Life Sciences. He also serves, or has recently served, as a Chair or non-executive director on the boards of several US healthcare companies including ZimVie (2022 - 2025), VaxCare (2021 - 2025), Privia Health, Health Channels, LGC and AmSurg Corporation. David served as executive chair and CEO for Laboratory Corporation of America (LabCorp) from 2007 to 2020 and prior to that was a partner at Hogan & Hartson LLP (now Hogan Lovells).
お知らせ • Jun 10Smith+Nephew Announces the Introduction of A New Medial Stabilized Insert for Its Legion Total Knee SystemSmith+Nephew announced the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023. With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone- conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient. The medial stabilized design aims to maintain stability with a larger anterior medial lip and medial pivot kinematics similar to the natural knee. The LEGION Medial Stabilized TKS stands out in this space - offering a powerful combination of medial stabilized kinematics, advanced porous fixation, integration with technologies like the CORI* Surgical System, and a strong clinical legacy. It's an ideal solution for surgeons looking to align with the principles of personalized care. The LEGION MedialStabilized TKS has demonstrated more than 20 years of clinical success, with the new medial stabilized insert adding a modern design to align with rapidly growing market trends. The LEGION Medial STabilized TKS is the latest addition to the LEGION portfolio supporting both the LEGION CONCELOC Cementless and LEGION Cemented Total Knee Systems. The medial stabilized insert for LEGION TKS is available in the US on a limited basis, with a full commercial release later in 2025. The system will also be introduced in Canada in 2026.
お知らせ • May 15Smith+Nephew Announces A Comparative sNPWT Study of 10,000+ C-sections Shows PICO™ sNPWT Reduces Complications and Cuts Healthcare Costs by $728,000 Per 1,000 PatientsSmith+Nephew announced findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew’s leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure levels, the study published in WOUNDS (April 2025) reveals that PICO sNPWT contributes to a significant reduction in surgical site complications (SSCs), including a reduction in the incidence of surgical site infections (SSIs), wound dehiscence and seroma, and overall costs, compared to another sNPWT device (P=0.05). New survey: The real-life burden of C-section complications: A complementary survey of new mothers who have undergone C-sections highlighted the impact of SSCs on both mother and baby: Mothers with complications reported requiring hospital readmissions; Are 5 times more likely to describe their recovery as traumatic; Over half (55%) reported feeling depressed than those that reported no complications; Are 5.4 times more likely to be unable to breastfeed; Two in three mothers (66.3%) reported that their overall c-section recovery impacted their ability to bond with their baby. Real-world data shows the clinical and economic benefits of using PICO sNPWT in patients undergoing C-section procedures: The study used real-world evidence from the Premier PINC AI™ Healthcare Database to analyze outcomes from a geographically diverse mix of community hospitals, teaching hospitals and healthcare systems across the US. Notable findings include significant reductions with PICO sNPWT, compared to other sNPWT devices in the incidence of: Overall SSIs (p=0.018); Superficial SSIs (p=0.017); Wound dehiscence (p=0.005); Seroma formation(p=0.050). PICO sNPWT is proven to reduce the odds of surgical site infections (SSIs), which could facilitate early mother and baby bonding and positively impacts on the patient’s emotional wellbeing.
お知らせ • May 02Smith & Nephew plc Maintains Earnings Guidance for the Full Year 2025Smith & Nephew plc maintained earnings guidance for the full year of 2025. For the period, the company guidance is unchanged: Underlying revenue growth expected to be around 5.0% (reported growth 5.4%), and significant trading profit margin expansion to between 19.0% and 20.0%. Continued higher cadence of product launches and clinical evidence contributing to growth. Unchanged outlook includes an expected net impact of $15 to $20 million from tariffs in 2025, based on announced measures, and mitigations.
お知らせ • Apr 25Smith & Nephew plc Announces Steps Down of Bob White as an Independent Non-Executive Director, Effective 30 April 2025Smith & Nephew plc announced that Bob White has informed the Board that he will be stepping down as an Independent Non-Executive Director on 30 April 2025 and will not submit himself for re-election at the Company's Annual General Meeting to be held on 30 April 2025.
お知らせ • Mar 11Smith & Nephew plc, Annual General Meeting, Apr 30, 2025Smith & Nephew plc, Annual General Meeting, Apr 30, 2025. Location: the smith nephew academy london, building 5, croxley park, hatters lane, wd18 8ye, watford United Kingdom
お知らせ • Mar 10Smith & Nephew plc to Report First Half, 2025 Results on Jul 31, 2025Smith & Nephew plc announced that they will report first half, 2025 results on Jul 31, 2025
お知らせ • Feb 25+ 1 more updateSmith & Nephew plc Recommends Final Dividend for 2024, Payable on May 28, 2025The Board of Smith & Nephew plc is recommending a Final Dividend of 23.1 cents per share (46.2 cents per ADS) (2023: 23.1 cents per share). Together with the Interim Dividend of 14.4 cents per share (28.8 cents per ADS), this will give a total distribution of 37.5 cents per share (75.0 cents per ADS), unchanged from 2023. Subject to confirmation at Annual General Meeting, the Final Dividend will be paid on 28 May 2025 to shareholders on the register at the close of business on 28 March 2025.
お知らせ • Jan 14Smith & Nephew plc Announces Board and Committee ChangesSmith+Nephew announced that Sybella Stanley will join the Board as an independent Non-Executive Director with effect from 1 February 2025. Sybella will serve as a member of the Remuneration Committee and will succeed Angie Risley as Chair of the Remuneration Committee with effect from 30 June 2025. Sybella has worked for RELX Plc since 1997 and is currently Director of Corporate Finance. She retired in December 2024 from the Board of Tate & Lyle plc where she served for nine years as an Independent Non-Executive Director and was Chair of the Remuneration Committee. She served for nine years as an Independent Non-Executive Director of Merchants Trust PLC and as Senior Independent Director and Chair of the Remuneration Committee until her retirement in March 2024. She is also co-chair of the Development Board of Somerville College, Oxford.
お知らせ • Dec 19Smith+Nephew Introduces CORIOGRAPH Pre-Op Planning and Modeling Services for Total Hip ArthroplastySmith+Nephew announced its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and modeling, enabling surgeons to make a patient-specific plan for the best possible outcome. The first procedures using CORIOGRAPH Pre- Op Planning and Modeling Services for Hip with RI.HIP solutions were recently completed by Dr. George Haidukewych, Surgeon in Chief and Academic Chairman at Orlando Health Jewett Orthopedic Institute in Orlando, FL. The CORI Surgical System offers proprietary tools and software across the full suite of procedure solutions to deliver a platform that is flexible and scalable across knee and hip joint arthroplasty indications. Built on 15+ years of clinical expertise and over 350,000 image-based hip and knee surgery plans, CORIOGRAPH Pre-op Planning and Modeling Services for hip is designed to optimize implant planning and personalization, including: Advanced modeling capabilities that utilize patient specific spinopelvic classification and pelvic tilt go beyond the mechanics of simple range-of-motion to simulate activities of daily living that help surgeons make decisions on optimal implant placement. Image-agnostic planning capabilities with 2D and/or 3D images to help personalize the end-to-end care specifically to the patient need. Can be used across the entire spectrum of Smith+Nephew hip implant solutions and technologies. CORIOGRAPH Pre-OP Planning and Modeling Services combined with RI.HIP solutions and the recently launched CADALYSTEM Primary Hip System, offer a complete solution for primary total hip arthroplasty.
お知らせ • Nov 02Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025Smith & Nephew plc provided earnings guidance for the full year 2024 and for 2025. For the full year, company expected underlying revenue growth to be around 4.5% (previously 5.0% to 6.0%), primarily due to the impact of China headwind. For trading profit margin in 2024, company now expecting growth of up to 50bpscompared to last year's 17.5% (previously at least 18.0%), reflecting the reduced operating leverage from slower revenue growth. For 2025, given the updated 2024 outlook and, in particular, uncertainty around ongoing China headwinds, company now expects to expand trading profit margin significantly to between 19.0% and 20.0%, driven by the continued delivery of the 12-Point Plan improvements.
お知らせ • Oct 31Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025Smith & Nephew plc announced that they will report fiscal year 2024 results on Feb 25, 2025
お知らせ • Oct 02Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)Smith+Nephew announced that its LEGION Hinged Knee (HK) System is now available in the United States with proprietary OXINIUM (Oxidized Zirconium) implant technology that delivers the durability of metals, the wear resistance of ceramics, and corrosion resistance better than both. Part of the LEGION Total Knee (TK) System, the LEGION HK System is designed to provide a natural range of motion with medial pivot, lateral roll back, and screw home. Since 2011, the LEGION HK System has enabled surgeons to transition intraoperatively from a constrained revision knee implant to a CoCr-hinged assembly. The award winning OXINIUM Technology has demonstrated lower inflammatory response, superior wear resistance and reduced surface damage, and fewer signs of corrosion damage compared to cobalt chrome, ultimately helping to mitigate common risk factors associated with revision procedures. LEGION revision with proprietary OXINIUM Technology has established itself as the best performing bearing with the lowest risk of re-revision compared to the class average.
お知らせ • Sep 27Smith+Nephew Announces Board and Committee ChangesSmith+Nephew announced that Angie Risley has been appointed as Senior Independent Director with effect from 1 October 2024. She will remain as Chair of the Remuneration Committee and a member of the Nomination & Governance Committee. Ms Risley succeeds Marc Owen who will remain the Chair of the Compliance & Culture Committee, and a member of the Audit and Nomination & Governance Committees.
お知らせ • Aug 02+ 1 more updateSmith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024Smith & Nephew plc provided earnings guidance for the second half and reaffirms earnings guidance for the Year 2024. For the second half, The company expects higher revenue growth in the second half than the first. The guidance for 2024 is unchanged. The company's underlying revenue growth expected in the range of 5.0% to 6.0% (4.4% to 5.4% reported), and trading profit margin expected to be at least 18.0%.
お知らせ • Jul 17Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip SystemSmith+Nephew announced it has received 510(k) clearance for its new CATALYSTEM Primary Hip System from the United States Food and Drug Administration. The system is designed to address the evolving demands of primary hip surgery including the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs). Advancements in primary hip arthroplasty include a shift to a shorter, proximally filling stem that is easier to prepare and insert using the direct anterior approach - a less invasive procedure that may enable improved range-of-motion and faster recovery for patients. This segment fits a diverse range of patient anatomies and is rapidly growing at a compound annual growth rate >10%. Building on the heritage of Smith+Nephew's clinically successful stem designs, the CATALYSTEM Primary Hip system was developed using global data sets across femoral morphologies to help deliver a precision fit. Featuring a triple-taper stem design with uniform proximal loading, the reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches. The CATALYSTEM Primary hip System also utilizes proprietary, patent-pending, ACCUBROACH Technology delivering proven reproducibility between broach and implant giving confidence in predictable and reproducible stem seating.
お知らせ • Jul 05Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.) on July 4, 2024.Cevian Capital II GP Limited completed the acquisition of 5.02% stake in Smith & Nephew plc (LSE:SN.) on July 4, 2024.
お知らせ • May 10Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024Smith & Nephew plc announced a final dividend of 23.1 US cents per ordinary share in respect of the year ended 31 December 2023 will be paid on 22 May 2024 to shareholders whose name appeared on the Register at the close of business on 2 April 2024. Those shareholders whose address on the Register is in the UK, and those who have validly elected to receive sterling dividends, will receive a dividend of 18.49 pence per share.
お知らせ • May 01Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024Smith & Nephew plc announced that they will report first half, 2024 results on Aug 01, 2024
お知らせ • Apr 02Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy SystemSmith+Nephew announced the launch of its RENASYS EDGE Negative Pressure Wound Therapy System in the US as a patient-centric option for treating chronic wounds. The system is lightweight and compact allowing it to be easily carried or worn, it features a discreet canister, and operates quietly so as not to draw attention or disturb the patients’ daily activities. It is estimated that the annual financial burden of chronic wounds in the US is $33 billion, and affecting some 8.2 million people. The RENASYS EDGE System is designed for patients suffering from these wounds and living at home. Chronic wounds, including ulcers, have a huge impact on a patient’s life beyond just the pain and discomfort, with 68% often becoming self-conscious of their wound and many becoming isolated. The need to carry a bulky, noisy medical device that draws attention to their condition only increases this discomfort. Smith+Nephew is also announcing two new national distribution partners for the RENASYS EDGE System - SunMED Medical Solutions and First Nation Group. These new partnerships will enable Smith+Nephew to introduce this new, innovative technology to more patients on a national level and support its growing negative pressure wound therapy business. For clinicians, the RENASYS EDGE system is intuitive and easy-to-use. Its user-friendly interface gives step-by-step guidance on therapy application, and technical support is just one click away during set up with the near field communication feature on the system. Additionally, Smith+Nephew provides 24-hour customer support for patients and a clinical hotline.
お知らせ • Mar 28+ 1 more updateSmith & Nephew plc Announces Board ChangesSmith & Nephew plc announced that John Rogers will join the Board as an Executive Director on 1 April 2024, succeeding Anne-Francoise Nesmes whose last day on the Board will be 31 March 2024.
お知らせ • Mar 12Smith & Nephew plc, Annual General Meeting, May 01, 2024Smith & Nephew plc, Annual General Meeting, May 01, 2024, at 11:00 Coordinated Universal Time. Location: Smith+Nephew Academy London, Building 5, Croxley Park, Hatters Lane, Watford, WD18 8YE Watford, London United Kingdom
お知らせ • Feb 29+ 1 more updateSmith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024Smith & Nephew plc is recommending a Final Dividend of 23.1¢ per share (46.2¢ per ADS) (2022: 23.1¢ per share). Together with the Interim Dividend of 14.4¢ per share (28.8¢ per ADS), this will give a total distribution of 37.5¢ per share (75.0¢ per ADS), unchanged from 2022. Subject to confirmation at Annual General Meeting, the Final Dividend will be paid on May 22, 2024 to shareholders on the register at the close of business on April 2, 2024.
お知らせ • Feb 13+ 1 more updateSmith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual MeetingSmith+Nephew announced full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025. Developed to restore patients' range-of-motion2-5 and help minimize arthritic shoulder pain, the AETOS Shoulder System features the Meta Stem which is designed for stability with metaphyseal fixation and an inlay collar, bone preservation, and to maintain patient anatomy. Indicated for both anatomic and reverse total shoulder arthroplasty, the AETOS Shoulders System offers a compact yet comprehensive portfolio of solutions that enhance the surgical experience by enabling intraoperative flexibility. With fewer steps for conversion and fewer instruments for primary anatomic and reverse, the system is designed to simplify the operating room flow. This also allows for an efficient solution, particularly of value in an Ambulatory Service Center (ASC) environment where sterilization and space limitations may be of concern. Fast turnaround time from image upload to planning. An optional 3D-printed glenoid guide, designed with the patented coracoid clip for stability, provides a reliable and accurate method to execute the surgical plan through conventional surgical techniques. The AETOS Shoulder System received 510(k) clearance from the United States Food and Drug Administration in June of 2023. It is the latest addition to Smith+Nephew's expanding Upper Extremity portfolio and complements market-leading Sports Medicine shoulder repair solutions to enable biological healing.
お知らせ • Jan 11+ 1 more updateSmith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled TrialSmith & Nephew plc announced standout results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online in Arthroscopy in December, the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant had better tendon healing compared to the standard of care, as evidenced by: A significantly lower re-tear rate (8.3 vs 25.8%; p=0.01), A three times lower risk of re-tear (RR=0.32; 95% CI:0.13–0.83) and No difference in the number of serious or minor complications. The blinded, multi-centre RCT compared the healing rate of full-thickness rotator cuff tears repaired with and without augmentation with the REGENETEN Bioinductive Implant. In total, 124 patients with reparable medium and large (1–4cm) full-thickness posterosuperior rotator cuff tears were randomized to receive either an arthroscopic transosseous equivalent double-row rotator cuff repair or the same repair augmented with the REGENETEN Bioinductive Implant. With more than 100,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for more than 1 million people having surgery for a rotator cuff tear each year. The collagen-based implant supports the body’s natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.
お知らせ • Dec 07Smith+Nephew Announces Board ChangesSmith+Nephew announced that Rick Medlock has notified the Board of his decision not to submit himself for re-election as a Non-Executive Director at the next annual general meeting of the Company. Jez Maiden, Non-Executive Director, will be appointed Chair of the Audit Committee with effect from 1 March 2024. The Board would like to thank Rick for his commitment and contribution to the Board and the Company and to congratulate Jez on his new appointment. joined the Board in 2023 and has extensive financial experience across a diverse range of industries and sectors. Jez was Chief Financial Officer of 5 UK-listed companies over a period of 24 years and has served as a Non-Executive Director on boards of companies addressing strategic and operational challenges across a number of different industries, including life-sciences and healthcare. He was previously Chair of the Audit Committee at Synthomer PLC and PZ Cussons plc. Current external appointments; Senior Independent Director, Travis Perkins plc. Non-Executive Director and member of the Audit Committee at Intertek Group plc. Jez retired in 2023 as Group Finance Director at Croda International plc, the FTSE 100 global speciality chemicals company, and previously held similar roles at National Express Group plc and Northern Foods Limited. He has served as the Senior Independent Director at Synthomer PLC and at both PZ Cussons plc and Synthomer PLC he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants.
お知らせ • Nov 24Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million on November 22, 2023. Under the terms of transaction, initial cash consideration of $180 million at closing and up to a further $150 million contingent on financial performance will be paid. The acquisition will be financed from existing cash and debt facilities. All CartiHeal employees are expected to transfer to Smith+Nephew. The transaction is expected to close in the first quarter of 2024.
お知らせ • Nov 04Smith & Nephew plc Provides Earning Guidance for Full Year 2023Smith & Nephew plc provided earning guidance for full year 2023. For the period, underlying revenue growth currently expected to be towards the higher end of guided range of 6.0% to 7.0% and trading profit margin now expected to be around 17.5%, reflecting headwinds from china.
お知らせ • Nov 02Smith & Nephew plc Announces Appointment of John Rogers as CFOSmith & Nephew plc announced that John Rogers will succeed Anne-Françoise Nesmes as Chief Financial Officer. He will join the company as Chief Financial Officer-designate on 1 December 2023 and, following a period of induction, will join the Board as Chief Financial Officer in the first quarter of 2024. Anne-Françoise's intention to step down as Chief Financial Officer was announced on 3 August 2023, and she has agreed to remain on the Board to finalise the 2023 Annual Report and Accounts and support an effective transition. John has extensive financial and commercial leadership experience across a range of sectors and on a global basis, as well as a track record of delivering complex international transformation programmes. He has served as the Chief Financial Officer of two FTSE-100 companies. He was most recently Chief Financial Officer at WPP plc where he successfully led the implementation of their global transformation programme. Prior to WPP, John was Chief Financial Officer at J Sainsbury plc and also served as Chief Executive Officer ofArgos, Habitat and Sainsbury's clothing and general merchandise businesses, where he led a major digitisation programme, driving increased market share and double-digit profit growth.
お知らせ • Oct 22Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023Smith & Nephew plc announced on 3 August 2023, an interim dividend for 2023 of 14.4 US cents per ordinary share will be paid on 1 November 2023 to shareholders whose names appeared on the Register at the close of business on 6 October 2023. Those shareholders whose address on the Register is in the UK, and those who have validly elected to receive sterling dividends, will receive a dividend of 11.89 pence per share.
お知らせ • Sep 14Smith & Nephew plc Announces Board and Committee ChangesSmith+Nephew announced that Jeremy (Jez) Maiden and Simon Lowth will be joining the Board as independent Non-Executive Directors. Jez joins and will serve as a member of the Audit Committee and Remuneration Committee. Simon will join on 1 January 2024 and will serve as a member of the Audit Committee and Nomination & Governance Committee. Additionally,Rupert Soames will, as planned,assume the role as Chair of the Board on 15 September, in succession to Roberto Quarta. Rupert has also been appointed as Chair of the Nomination & Governance Committee and will continue to serve on the Remuneration Committee. Jez Maiden has extensive global financial experience across a diverse range of industries and sectors. He retired earlier this year as Group Finance Director at Croda International, the FTSE-100 global speciality chemicals company, and before that held similar roles at National Express Group and Northern Foods. He is currently Senior Independent Director at Travis Perkins plc and a Non-Executive Director and member of the Audit Committee at Intertek Group plc. Previously, he served as the Senior Independent Director at Synthomer and at both PZ Cussons and Synthomer he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants. Simon Lowthhas deep experience in finance, accounting, risk, corporate strategy as well as mergers and acquisitions.He currently serves as Group Chief Financial officer of BT Group, a role he has held since 2016 and previously performed the same role at BG Group, AstraZeneca and Scottish Power.Before joining Scottish Power, he led the Industrial Practice of McKinsey in the UK and has a background in engineering. He previously served as a Non-Executive Director on the Board of Standard Chartered. He currently holds no additional external appointments.
お知らせ • Aug 04Smith & Nephew plc Increases Revenue Guidance for 2023Smith & Nephew plc announced full year guidance for 2023. For the year, the company expects revenue growth guidance of 6.0% to 7.0% (previously 5.0% to 6.0%).
お知らせ • Aug 03Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial OfficerSmith & Nephew plc announced that Anne-Françoise Nesmes has informed the Board of her intention to step down as Chief Financial Officer during the second quarter of 2024, on a date to be agreed. The Board has initiated an external search for her successor.
お知らせ • Jun 13Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder SystemSmith+Nephew announced that it has received 510(k) clearance from the United States Food and Drug Administration for its AETOS Shoulder System. Designed to restore patients' range-of-motion1-4 and help minimize arthritic shoulder pain. Features the AETOS Meta Stem - designed to maximize stability, preserve bone, and maintain patient anatomy. Indicated for both anatomic and reverse total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025. For healthcare professionals, the AETOS Shoulder System offers a compact yet comprehensive portfolio of solutions that enhance the surgical experience by enabling intraoperative flexibility. With fewer steps for conversion and fewer instruments for primary anatomic and reverse, the system is designed to simplify the operating room flow. The AETOS Shoulder System is the latest solution in Smith+Nephew's expanding Upper Extremity portfolio and complements market leading Sports Medicine shoulder repair and biologics solutions.
お知らせ • Feb 17+ 1 more updateSmith & Nephew plc, Annual General Meeting, Apr 26, 2023Smith & Nephew plc, Annual General Meeting, Apr 26, 2023. Agenda: To elect independent non-executive director.
お知らせ • Nov 04Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023Smith & Nephew plc announced that they will report fiscal year 2022 results on Feb 21, 2023
お知らせ • Sep 13+ 1 more updateSmith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023Smith & Nephew plc announced that they will report Q2, 2023 results on Aug 03, 2023
